Open AccessPAPP ‐A: a promising therapeutic target for healthy longevity
Author(s) -
Conover Cheryl A.,
Oxvig Claus
Publication year - 2017
Publication title -
aging cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.103
H-Index - 140
eISSN - 1474-9726
pISSN - 1474-9718
DOI - 10.1111/acel.12564
Subject(s) - biology , longevity , microbiology and biotechnology , pregnancy associated plasma protein a , receptor , cleavage (geology) , endocrinology , genetics , pregnancy , fetus , paleontology , first trimester , fracture (geology)
Summary Pregnancy‐associated plasma protein‐A ( PAPP ‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor ( IGF ) availability for receptor activation through cleavage of inhibitory IGF binding proteins ( IGFBP s). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP ‐A represents a novel approach to indirectly decrease the availability of bioactive IGF . Here, we will review data in support of PAPP ‐A as a therapeutic target to promote healthy longevity.